Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Greuter MJE, Coupé VMH, Canfell K.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1450-1461. doi: 10.1158/1055-9965.EPI-18-0128. Epub 2018 Sep 6.

PMID:
30190276
2.

Performance Evaluation of a Semi-automated Method for [18F]FDG Uptake in Abdominal Visceral Adipose Tissue.

de Boer SA, Spoor DS, Slart RHJA, Mulder DJ, Reijrink M, Borra RJH, Kramer GM, Hoekstra OS, Boellaard R, Greuter MJ.

Mol Imaging Biol. 2018 May 22. doi: 10.1007/s11307-018-1211-1. [Epub ahead of print]

PMID:
29789994
3.

Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.

Bronzwaer MES, Greuter MJE, Bleijenberg AGC, IJspeert JEG, Dekker E, Coupé VMH.

BMC Cancer. 2018 Apr 25;18(1):465. doi: 10.1186/s12885-018-4375-9.

4.

Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study.

Buitenwerf E, Korteweg T, Visser A, Haag CMSC, Feelders RA, Timmers HJLM, Canu L, Haak HR, Bisschop PHLT, Eekhoff EMW, Corssmit EPM, Krak NC, Rasenberg E, van den Bergh J, Stoker J, Greuter MJW, Dullaart RPF, Links TP, Kerstens MN.

Eur J Endocrinol. 2018 May;178(5):431-437. doi: 10.1530/EJE-18-0006. Epub 2018 Feb 21.

PMID:
29467230
5.

Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.

Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Sarfati D, Greuter MJE, Coupé VMH, Canfell K.

Int J Cancer. 2018 Jul 15;143(2):269-282. doi: 10.1002/ijc.31314. Epub 2018 Mar 8.

PMID:
29441568
6.

Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.

Lew JB, St John DJB, Xu XM, Greuter MJE, Caruana M, Cenin DR, He E, Saville M, Grogan P, Coupé VMH, Canfell K.

Lancet Public Health. 2017 Jul;2(7):e331-e340. doi: 10.1016/S2468-2667(17)30105-6. Epub 2017 Jun 26.

7.

Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program.

Vleugels JLA, Greuter MJE, Hazewinkel Y, Coupé VMH, Dekker E.

Endosc Int Open. 2017 Dec;5(12):E1197-E1207. doi: 10.1055/s-0043-113565. Epub 2017 Nov 22.

8.

Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.

Greuter MJE, de Klerk CM, Meijer GA, Dekker E, Coupé VMH.

Ann Intern Med. 2017 Oct 17;167(8):544-554. doi: 10.7326/M16-2891. Epub 2017 Oct 3.

PMID:
28973514
9.

Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI.

Greuter MJ, Schouten CS, Castelijns JA, de Graaf P, Comans EF, Hoekstra OS, de Bree R, Coupé VM.

BMC Cancer. 2017 Apr 11;17(1):256. doi: 10.1186/s12885-017-3254-0.

10.

Resilience of a FIT screening programme against screening fatigue: a modelling study.

Greuter MJ, Berkhof J, Canfell K, Lew JB, Dekker E, Coupé VM.

BMC Public Health. 2016 Sep 22;16(1):1009.

11.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Greuter MJ, Berkhof J, Fijneman RJ, Demirel E, Lew JB, Meijer GA, Stoker J, Coupé VM.

Br J Radiol. 2016 Jul;89(1063):20150910. doi: 10.1259/bjr.20150910. Epub 2016 May 19.

12.

Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.

Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, Dekker E, Meijer GA, Coupé VM.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):135-44. doi: 10.1158/1055-9965.EPI-15-0592. Epub 2015 Nov 23.

13.

The Potential of (TARGETED) MR Colonography as a Screening Tool for Colorectal Cancer: A Cost-Effectiveness Analysis.

Greuter MJ, Demirel E, Berkhof J, Fijneman RJ, Stoker J, Meijer GA, Coupé VM.

Value Health. 2014 Nov;17(7):A631-2. doi: 10.1016/j.jval.2014.08.2260. Epub 2014 Oct 26. No abstract available.

14.

Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway.

Greuter MJ, Lew JB, Berkhof J, Canfell K, Dekker E, Meijer GA, Coupe VM.

Value Health. 2014 Nov;17(7):A323. doi: 10.1016/j.jval.2014.08.565. Epub 2014 Oct 26. No abstract available.

15.

Modeling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA).

Greuter MJ, Xu XM, Lew JB, Dekker E, Kuipers EJ, Canfell K, Meijer GA, Coupé VM.

Risk Anal. 2014 May;34(5):889-910. doi: 10.1111/risa.12137. Epub 2013 Oct 31.

PMID:
24172539
16.

Quality of guidelines on the management of diabetes in pregnancy: a systematic review.

Greuter MJ, van Emmerik NM, Wouters MG, van Tulder MW.

BMC Pregnancy Childbirth. 2012 Jun 28;12:58. doi: 10.1186/1471-2393-12-58.

Supplemental Content

Loading ...
Support Center